Drugs / PUR3100
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05351086 | Jun → Sep 2022 | — | Pulmatrix Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PUR3100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05351086 ↗ |
| Action | Activate | “PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors.” NCT05351086 ↗ |
| Route | Inhaled | “dry powder inhalation of 0.5mg of PUR3100, 1.0 mg of PUR 3100, 1.5 mg of PUR 3100, or placebo.” NCT05351086 ↗ |